Who are Infliximab subcutaneous's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Smartject Device delivery of Golimumab, Start adalimumab in monotherapy, Adalimumab (Humira), Infliximab biosimilar, infliximab therapeutic drug monitoring, Golimumab treatment optimization..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/infliximab-subcutaneous.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infliximab subcutaneous — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infliximab subcutaneous (Infliximab subcutaneous) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (monoclonal antibody). Area: Immunology.

phase 3 TNF-α inhibitor (monoclonal antibody) TNF-α (tumor necrosis factor-alpha) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Infliximab subcutaneous (Infliximab subcutaneous) — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Infliximab subcutaneous TARGET	Infliximab subcutaneous	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	phase 3	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Smartject Device delivery of Golimumab	Smartject Device delivery of Golimumab	Merck Sharp & Dohme LLC	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Start adalimumab in monotherapy	Start adalimumab in monotherapy	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Adalimumab (Humira)	Adalimumab (Humira)	Tufts Medical Center	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Infliximab biosimilar	Infliximab biosimilar	Hanyang University Seoul Hospital	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
infliximab therapeutic drug monitoring	infliximab therapeutic drug monitoring	Imelda GI Clinical Research Center	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Golimumab treatment optimization.	Golimumab treatment optimization.	Hospital de Manises	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (monoclonal antibody) class)

Merck Sharp & Dohme LLC · 3 drugs in this class
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 2 drugs in this class
Hanyang University Seoul Hospital · 2 drugs in this class
Biocad · 1 drug in this class
Children's Memorial Health Institute, Poland · 1 drug in this class
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Hikma Pharmaceuticals LLC · 1 drug in this class
Hospital de Manises · 1 drug in this class
Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Infliximab subcutaneous — Competitive Intelligence Brief. https://druglandscape.com/ci/infliximab-subcutaneous. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing